FDA Grants Approval to Eli Lilly’s GLP-1 Diabetes Pill
The U.S. Food and Drug Administration (FDA) has granted approval to Eli Lilly’s new weight loss pill, Foundayo. This medication belongs to the GLP-1 class, which also includes well-known treatments such as Ozempic and Wegovy. Foundayo is specifically designed for obesity management and is the second GLP-1 pill approved for weight loss.
Key Features of Foundayo
Unlike traditional injectables, Foundayo is taken once daily and can be consumed at any time, without food or water restrictions. The active ingredient, orforglipron, mimics a hormone that helps regulate blood sugar and appetite, enhancing feelings of fullness. This convenience may attract those who prefer pills over injections.
- Manufacturer: Eli Lilly
- Type: GLP-1 weight loss medication
- Administration: Oral pill, taken once daily
- Active Ingredient: Orforglipron
- Expected Availability: April 6, 2023, via LillyDirect
Comparative Clinical Results
Clinical trials indicate promising outcomes for Foundayo. Participants taking the maximum dosage for 18 months lost an average of 27 pounds, equating to 12.4% of their body weight. In comparison, those receiving a placebo lost only 2 pounds. While Novo Nordisk’s Wegovy pill showed an average weight loss of 13.6% over 16 months, head-to-head efficacy studies comparing Foundayo and Wegovy have yet to be conducted.
Additional Insights and Market Implications
Pharmaceutical companies are racing to develop GLP-1 weight loss pills, responding to the high demand for injectable medications. Recent shortages were reported between late 2022 and early 2023 due to overwhelming demand. Ken Custer, Eli Lilly’s executive vice president, noted that the desire for a pill form could ease accessibility for many patients.
Future Considerations
Foundayo is also being investigated for potential uses in treating type 2 diabetes, obstructive sleep apnea, and osteoarthritis. This evolving role signifies the broader impact of GLP-1 drugs beyond just weight management.
As the market shifts towards easier administration methods, Eli Lilly anticipates broad distribution through U.S. retail pharmacies and telehealth services shortly after its initial availability date. With a streamlined 50-day FDA approval process, Foundayo is positioned to influence obesity treatment significantly.
